By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Mysterious bright blue cosmic blasts triggered by black holes shredding stars, scientists say. 'It's definitely not just an exploding star.' - 2Woman, 60, Is Finally Traveling the World Decades After Husband’s Death Held Her Back
- 3World’s tallest bridge and biggest museum named ‘greatest places of 2026’
- 4Artemis II astronauts are more than halfway to the moon as they seek to break Apollo 13's record
- 5Exploring the Market: Unsold Rams May Be Less expensive Than You Naturally suspect
- Why doing good also makes us feel good, during the holidays and beyond
- Inside Plan with Houseplants: An Aide
- Grasping Wrongdoings and Crimes: A Correlation
- Ukrainian troops showed 'greater tactical imagination' than Western trainers, British officer says, pointing to their ambush tactics
- Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- Somaliland denies trading recognition with Israel for accepting Gazans
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- My Dad Can't Travel Like He Used to, but Slowing Down Doesn't Mean Stopping
- People Are Sharing The One Picture They Can't See Without Laughing, And It's The Comedy Spiral You Need Today
